P-230: Preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib
Clinical Lymphoma Myeloma and Leukemia(2022)
关键词
bortezomib,mezigdomide,translational biomarker analysis,mezigdomide,carfilzomib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要